Thomas Mürdter
Thomas Mürdter
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
W Schroth, L Antoniadou, P Fritz, M Schwab, T Muerdter, UM Zanger, ...
Journal of Clinical Oncology 25 (33), 5187-5193, 2007
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy
W Solass, R Kerb, T Mürdter, U Giger-Pabst, D Strumberg, C Tempfer, ...
Annals of surgical oncology 21 (2), 553-559, 2014
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
J Kirchheiner, C Klein, I Meineke, J Sasse, UM Zanger, TE Mürdter, ...
Pharmacogenetics and Genomics 13 (10), 619-626, 2003
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine
T Richter, TE Mürdter, G Heinkele, J Pleiss, S Tatzel, M Schwab, ...
Journal of Pharmacology and Experimental Therapeutics 308 (1), 189-197, 2004
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma
TE Mürdter, W Schroth, L Bacchus‐Gerybadze, S Winter, G Heinkele, ...
Clinical Pharmacology & Therapeutics 89 (5), 708-717, 2011
P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans
S Drescher, H Glaeser, T Mürdter, M Hitzl, M Eichelbaum, MF Fromm
Clinical Pharmacology & Therapeutics 73 (3), 223-231, 2003
Pharmacogenomics of tamoxifen therapy
H Brauch, TE Murdter, M Eichelbaum, M Schwab
Clinical chemistry 55 (10), 1770-1782, 2009
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy
MH Olofsson, T Ueno, Y Pan, R Xu, F Cai, H Van Der Kuip, TE Muerdter, ...
Clinical Cancer Research 13 (11), 3198-3206, 2007
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, ...
The pharmacogenomics journal 15 (1), 84-94, 2015
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liver
JK Coller, N Krebsfaenger, K Klein, K Endrizzi, R Wolbold, T Lang, ...
British journal of clinical pharmacology 54 (2), 157-167, 2002
Role of P-glycoprotein inhibition for drug interactions
S Eberl, B Renner, A Neubert, M Reisig, I Bachmakov, J König, F Dörje, ...
Clinical pharmacokinetics 46 (12), 1039-1049, 2007
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters
H Brauch, W Schroth, MP Goetz, TE Mürdter, S Winter, JN Ingle, ...
Journal of Clinical Oncology 31 (2), 176, 2013
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment
H van der Kuip, TE Mürdter, M Sonnenberg, M McClellan, S Gutzeit, ...
BMC cancer 6 (1), 1-11, 2006
Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib
SS Brenner, C Herrlinger, K Dilger, TE Mürdter, U Hofmann, C Marx, ...
Clinical pharmacokinetics 42 (3), 283-292, 2003
Enhanced uptake of doxorubicin into bronchial carcinoma: β-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site
TE Mürdter, B Sperker, KT Kivistö, M McClellan, P Fritz, G Friedel, ...
Cancer research 57 (12), 2440-2445, 1997
Genetic polymorphisms of glutathione S‐transferase A1, the major glutathione S‐transferase in human liver: consequences for enzyme expression and busulfan conjugation
M Bredschneider, K Klein, TE Mürdter, C Marx, M Eichelbaum, AK Nüssler, ...
Clinical Pharmacology & Therapeutics 71 (6), 479-487, 2002
Expression and function of β-glucuronidase in pancreatic cancer: potential role in drug targeting
B Sperker, U Werner, TE Mürdter, C Tekkaya, P Fritz, R Wacke, U Adam, ...
Naunyn-Schmiedeberg's archives of pharmacology 362 (2), 110-115, 2000
The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells
S Taetz, N Nafee, J Beisner, K Piotrowska, C Baldes, TE Mürdter, ...
European journal of pharmaceutics and biopharmaceutics 72 (2), 358-369, 2009
Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux
S Igel, S Drescher, T Mürdter, U Hofmann, G Heinkele, H Tegude, ...
Clinical pharmacokinetics 46 (9), 777-785, 2007
Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells.
I Siegle, P Fritz, M McClellan, S Gutzeit, TE Mürdter
Anticancer research 21 (4A), 2687-2691, 2001
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20